Sorafenib Monotherapy in a Patient with Unresectable Hepatic Epithelioid Hemangioendothelioma

25Citations
Citations of this article
14Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

A 49-year-old Japanese man had multiple huge masses (max. size 60 mm diameter) in his liver. These tumors were pathologically diagnosed by tumor biopsy as epithelioid hemangioendotheliomas of the liver. In this case, multiple liver tumors existed in both lobes. Also this patient did not agree to receive surgical resection including liver transplantation. Chemotherapy with sorafenib at a dose of 400 mg/body twice a day was started. About 6 months later, CT findings revealed that these tumors were shrinking slightly; 33 months later, the tumors obviously showed a partial response in accordance with the Response Evaluation Criteria in Solid Tumors (RECIST). Also 60 months later, the partial response continued with sorafenib monotherapy.

Cite

CITATION STYLE

APA

Kobayashi, N., Shimamura, T., Tokuhisa, M., Goto, A., & Ichikawa, Y. (2016). Sorafenib Monotherapy in a Patient with Unresectable Hepatic Epithelioid Hemangioendothelioma. Case Reports in Oncology, 9(1), 134–137. https://doi.org/10.1159/000443986

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free